Jeffrey Glenn, MD, PhD
Co-founder of EIT Pharma, Inc., Director. Professor of Medicine at Stanford University
Dr. Glenn is the Joseph D. Grant Professor of Medicine (Division of Gastroenterology & Hepatology) and Microbiology & Immunology at Stanford University, Director of ViRx@Stanford, the Stanford Biosecurity and Pandemic Preparedness Initiative, and Deputy Director for Entrepreneurship and Innovation of the Sarafan ChEM-H Institute. He has over 30 years of experience in basic science and clinical drug development. With demonstrated experience in molecular virology and the translation of that knowledge into novel antiviral therapies, his inventions and efforts have helped found new companies focused on developing drugs from technologies developed in his lab, with six different drugs currently in development (two of which completed successful phase III studies) as a result. Dr. Glenn is also the PI on a U19 Antiviral Drug Discovery (AViDD) Center, SyneRx. He received his A.B. degree, summa cum laude with a double major in biochemistry and French civilization from U.C. Berkeley. He received his M.D. and Ph.D. in biochemistry and biophysics from the U.C.S.F. MSTP program.
He discovered the critical role of prenylation in the life cycle of hepatitis delta virus (HDV) and its role in mediating assembly and release of new HDV virus particles--which is the rationale for treating delta hepatitis with Jitixib®—and spearheaded the clinical development of Jitixib® for HDV from clinical proof-of-concept through the recently completed successful phase 3 D-LIVR study. He is also an inventor on the use of interferon lambda for HDV and COVID-19.